Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 1.00 |
| ▸ | HTR2C | P28335 | 8/20 | 0.67 |
| ▸ | HTR2B | P41595 | 6/20 | 0.66 |
| ▸ | HTR1A | P08908 | 3/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR1B | P28222 | 1/20 | 0.66 |
| ▸ | HTR1E | P28566 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
| ▸ | HTR7 | P34969 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | HTR5A | P47898 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352648 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL26965635 | 0.91 | HTR2A (0.83) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL25030287 | 0.86 | HTR2A (0.76) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL29992340 | 0.86 | HTR2A (0.76) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL31614648 | 0.85 | HTR2A (0.74) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL25008699 | 0.85 | HTR2A (0.74) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL31027229 | 0.85 | HTR2A (0.74) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL29168426 | 0.85 | HTR2A (0.74) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL25008879 | 0.85 | HTR2A (0.74) | HTR2AHTR2CHTR2BHTR1ADRD1 | |
| SCHEMBL31027230 | 0.85 | HTR2A (0.74) | HTR2AHTR2CHTR2BHTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497637-B1 | Stabilization of tryptamines by denaturing enzymes, optimizing ionization states, and controlling confounding variables | Convergent Health Sciences LLC (US) | 2025-12-16 | — | — | US | claimed |
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | Convergent Health Sciences LLC: (US) | 2026-04-28 | — | — | US | disclosed |
| US-12503713-B1 | Stabilization of tryptamines by denaturing enzymes, optimizing ionization states, and controlling confounding variables | Convergent Health Sciences LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-12497637-B1 | Stabilization of tryptamines by denaturing enzymes, optimizing ionization states, and controlling confounding variables | Convergent Health Sciences LLC (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4551212-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | SYNAPTIVE THERAPEUTICS, LLC | 2024-11-07 | — | — | US | disclosed |
| CN-118055766-A | Magic and non-magic serotonin receptor agonist and its preparing process and usage | 库莱恩有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024035757-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4271682-A1 | METHOD OF SYNTHESIZING INDOLE COMPOUNDS | 1280225 B.C. Ltd. (CA) | 2023-11-08 | — | — | EP | disclosed |
| EP-4225320-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | Goodcap Pharmaceuticals Ltd. (CA) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023081842-A2 | ALTERNATIVE BIOSYNTHESIS PATHWAYS FOR THE PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022140844-A1 | METHOD OF SYNTHESIZING INDOLE COMPOUNDS | 1280225 B.C. LTD. (CA) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022079574-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | GOODCAP PHARMACEUTICALS LTD. (CA) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | PLCB1, PHKG1, PLCB3 | HTR2A 105/4885HTR2C 39/4885HTR2B 9/4885 |
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | HTR1B, HTR2B, PNMT | HTR2A 5/4885HTR2C 4/4885HTR2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.